Gustavo A. Rosario Benitez

Array ( [id] => 13536681 [patent_doc_number] => 20180319884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/035300 [patent_app_country] => US [patent_app_date] => 2018-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12391 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16035300 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15634433 [patent_doc_number] => 10590194 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-17 [patent_title] => T cell receptors and immune therapy using the same [patent_app_type] => utility [patent_app_number] => 16/023731 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 22733 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16023731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931167 [patent_doc_number] => 20200157217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => ANTI-CD3 ANTIBODIES AND METHODS OF MAKING AND USING THEREOF [patent_app_type] => utility [patent_app_number] => 16/615109 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8152 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17822704 [patent_doc_number] => 11427642 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Anti-BCMA heavy chain-only antibodies [patent_app_type] => utility [patent_app_number] => 16/622768 [patent_app_country] => US [patent_app_date] => 2018-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 5 [patent_no_of_words] => 11091 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16622768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13479107 [patent_doc_number] => 20180291096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => Methods of Treatment Using Human Anti-IL-23 Antibodies [patent_app_type] => utility [patent_app_number] => 16/013141 [patent_app_country] => US [patent_app_date] => 2018-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16013141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839552 [patent_doc_number] => 20210147564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/622881 [patent_app_country] => US [patent_app_date] => 2018-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10768 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16622881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13777967 [patent_doc_number] => 20190002522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS FOR DIRECT RECOGNITION OF TUMOR ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/008858 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16008858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209851 [patent_doc_number] => 20190367612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => ANTI-GPRC5D ANTIBODY AND MOLECULE CONTAINING SAME [patent_app_type] => utility [patent_app_number] => 16/483211 [patent_app_country] => US [patent_app_date] => 2018-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -82 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16483211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17814308 [patent_doc_number] => 11419895 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Compositions and methods of cellular immunotherapy [patent_app_type] => utility [patent_app_number] => 16/618047 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 36503 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16618047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413273 [patent_doc_number] => 20180258179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => A MONOCLONAL ANTIBODY AND A METHOD THEREOF [patent_app_type] => utility [patent_app_number] => 15/975681 [patent_app_country] => US [patent_app_date] => 2018-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14581 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15975681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102455 [patent_doc_number] => 11542330 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use [patent_app_type] => utility [patent_app_number] => 16/611832 [patent_app_country] => US [patent_app_date] => 2018-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 77 [patent_figures_cnt] => 68 [patent_no_of_words] => 71271 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13563773 [patent_doc_number] => 20180333434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => USE OF COMMON GAMMA CHAIN CYTOKINES FOR THE VISUALIZATION, ISOLATION AND GENETIC MODIFICATION OF MEMORY T LYMPHOCYTES [patent_app_type] => utility [patent_app_number] => 15/970945 [patent_app_country] => US [patent_app_date] => 2018-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20445 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 280 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15970945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13551851 [patent_doc_number] => 20180327473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => Human Alpha Fetoprotein-Specific Murine T Cell Receptors and Uses Thereof [patent_app_type] => utility [patent_app_number] => 15/969211 [patent_app_country] => US [patent_app_date] => 2018-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15969211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16061369 [patent_doc_number] => 10689619 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => T cell receptor-deficient T cell compositions [patent_app_type] => utility [patent_app_number] => 15/966103 [patent_app_country] => US [patent_app_date] => 2018-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 13982 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15966103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386411 [patent_doc_number] => 20180244747 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 15/965738 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47638 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15965738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13399943 [patent_doc_number] => 20180251514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 15/965739 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47409 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15965739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18070555 [patent_doc_number] => 11529371 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => Anti-CD33 antibody agents [patent_app_type] => utility [patent_app_number] => 16/607426 [patent_app_country] => US [patent_app_date] => 2018-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 30569 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16607426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17845985 [patent_doc_number] => 11435349 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => CD127 expression inversely correlates with FoxP3 and suppressive function of CD4 [patent_app_type] => utility [patent_app_number] => 15/958638 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 24768 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15958638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20143970 [patent_doc_number] => 12378297 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-05 [patent_title] => Chimeric antigen receptor T cells targeting the tumor microenvironment [patent_app_type] => utility [patent_app_number] => 16/603675 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 56 [patent_no_of_words] => 18240 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20143970 [patent_doc_number] => 12378297 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-05 [patent_title] => Chimeric antigen receptor T cells targeting the tumor microenvironment [patent_app_type] => utility [patent_app_number] => 16/603675 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 56 [patent_no_of_words] => 18240 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603675 [rel_patent_id] =>[rel_patent_doc_number] =>)